VSV-GP

VSV-GP (BI 1831169) is a recombinant, live-attenuated oncolytic chimeric virus derived from the vesicular stomatitis virus (VSV), a single-stranded RNA virus. Its neurotropic glycoprotein G has been replaced by the non-neurotropic glycoprotein GP of the lymphocytic choriomeningitis virus. This modification reduces neurotoxicity and enhances tumor selectivity. The drug acts as an oncolytic immunotherapy by selectively infecting and lysing cancer cells while sparing normal cells due to interferon-dependent tumor specificity. It also stimulates antitumor immune responses through viral replication in tumor cells, release of tumor antigens and cytokines, and subsequent activation of systemic immunity. VSV-GP is being developed primarily for advanced solid tumors as monotherapy or in combination with checkpoint inhibitors such as ezabenlimab[1][3][5][6][7].

Other names

vesicular stomatitis virus glycoprotein pseudotypedchimeric oncolytic virus